Skip to main content

Table 1 Outcomes, health effects and discounted costs for the baseline and QIV strategy

From: Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model

  Baseline Scenario: QIV switch for 6 m-5yo
New situation Difference
Clinical influenza B outcomes (per season)
 Total number of symptomatic cases 6,564,965 6,158,397 −406,569
 Total number outpatient visits 2,341,626 2,188,848 − 152,778
 Total number of hospitalizations 189,677 178,359 −11,318
 Total number of deaths 6596 6203 − 393
Health effects related to influenza B (per season)
 Total QALYs lost because of influenza illness 61,646 57,902 − 3744
 Total QALYs lost because of influenza-related deaths 47,861 45,304 − 2556
 Total life-years lost because of influenza-related deaths 63,711 60,313 − 3398
Discounted costs (R$)
 Vaccination 687,307,209 863,977,370 176,670,161
 Outpatient visit 92,744,270 87,410,202 −5,334,068
 Hospitalized 196,767,867 186,295,892 −10,471,974
 Death 20,417,936 19,332,171 −1,085,765
 Productivity losses 1,351,536,346 1,278,078,007 − 73,458,340
  1. Results are averaged over the 7 seasons considered. Only influenza B outcomes are considered since the switch to QIV only affects influenza B cases. Costs are discounted at 5% per year